A Spanish, Retrospective Observational Multicenter Study to Describe the Efficacy and Safety of Switching Jakinibs (JAKi) Baricitinib or Tofacitinib Sequentially in Any Order in Patients with Rheumatoid Arthritis (RA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary) ; Tofacitinib (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Jun 2020 New trial record
06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight